

Chemical biology of mutagenesis and DNA repair: cellular responses to DNA alkylation

Nidhi Shrivastav^{1,2}, Deyu Li^{1,2} and John M.Essigmann^{1,2,*}

¹Department of Biological Engineering and ²Department of Chemistry, Massachusetts Institute of Technology, Cambridge, MA 02139, USA

*To whom correspondence should be addressed. Tel: +1 6172536227;
Fax: +1 6172535445;
Email: jessig@mit.edu

The reaction of DNA-damaging agents with the genome results in a plethora of lesions, commonly referred to as adducts. Adducts may cause DNA to mutate, they may represent the chemical precursors of lethal events and they can disrupt expression of genes. Determination of which adduct is responsible for each of these biological endpoints is difficult, but this task has been accomplished for some carcinogenic DNA-damaging agents. Here, we describe the respective contributions of specific DNA lesions to the biological effects of low molecular weight alkylating agents.

Introduction

DNA damage can be caused by radiation, by organic and inorganic chemical agents and by enzymes that have the roles of promoting natural methylation and deamination, such as members of the *S*-adenosylmethionine (SAM)-dependent methyltransferases, the activation-induced deaminase and the apolipoprotein B editing complex (1,2). Because DNA is abundantly equipped with nucleophilic sites, reaction with extracellularly generated and endogenously produced electrophiles results in an amazingly diverse array of covalent chemical-DNA adducts. These lesions compromise cellular welfare in three major ways (Figure 1). First, misreplication or misrepair of the lesions triggers mutations, which can be the initiating lesions of genetic diseases, including cancer. Second, the lesions can jeopardize the epigenetic program imprinted by natural enzymatic DNA modifications. Finally, the lesions can block RNA and DNA polymerases and can lead directly or indirectly to DNA strand breaks, which tend to be lethal in most cells. The biological importance of DNA damage is evidenced by the large commitment of the genome to protection of informational integrity; such genoprotective networks include electrophile scavengers, recombination complexes that permit DNA lesion tolerance, specialized polymerases that afford lesion bypass and a large battery of DNA repair proteins. Loss of one or more of these networks results in loss of informational integrity and, ultimately, the onset of disease (1).

Once it was appreciated that DNA lesions cause mutagenic and toxic events, researchers sought to understand the relationships between the structure of each lesion in DNA and the biological endpoints indicated above (3). For example, discovery of the mutagenic lesion of a carcinogenic DNA-damaging agent might lead to strategies to reduce the level of that lesion in DNA and hence reduce the likeli-

hood of carcinogenesis. Studies on the DNA adducts of aflatoxin B₁ led to intervention strategies at the population level that offer promise of reducing liver cancer burden (4). As a second example, knowledge of the relationship between the structures of DNA adducts of anticancer drugs and cytotoxicity endpoints can aid drug development efforts in clinical pharmacology. While it is obvious that establishing the relationships between DNA adducts and their biological endpoints is important, it proved very difficult to develop an experimental strategy to address the problem. Even a single simple DNA-damaging agent such as the aforementioned aflatoxin results in nearly a dozen DNA adducts, which frustrated early attempts to determine which adducts are the biologically important ones (5).

Dissection of the relative biological importance of individual DNA lesions proved to be a tractable problem with the advent of methodology whereby investigators could place one lesion at a time into synthetic DNA (Figure 2). In early *in vitro* studies, the oligonucleotides with adducts at known sites were acted upon with purified polymerases (Figure 2A) and repair proteins, which gave results that helped predict the biological relevance of a lesion and helped define the cellular repair systems that might protect against it. A second step involved the use of shuttle vectors that were globally modified by a DNA-damaging agent (Figure 2B). Chemical or enzymatic tools allowed the mapping of some (but not all) lesion sites along a stretch of DNA. The damage spectrum was then compared with the spectrum of mutations that arose when the modified vector was replicated within cells. Often multiple types of mutation were observed at a single site and it was impossible to ascertain if a single lesion gave rise to multiple mutations at, for example, a guanine site or whether there were several distinct guanine adducts each of which had its own signature and singular mutation. Nevertheless, this approach was and continues to be a cornerstone of mutation research.

The fusion of chemistry and biology, termed ‘chemical biology’, gave rise to a more advanced technology in which synthetic oligonucleotides containing well-characterized single DNA lesions were genetically engineered into the genomes of viruses or plasmids, which could be introduced into bacterial or mammalian cells (Figure 2C). Within the cell, the lesion would encounter the host repair and replication systems much in the same way that the lesion would be treated if it had formed endogenously. Lethal endpoints could be measured as a decrease in viral or plasmid progeny. Mutagenic outcomes could be determined by interrogating the vector genomes in the vicinity of the genomic site that originally contained the adduct. The relative importance of various DNA repair and polymerase systems to deal with or process the adduct could be determined by introduction of the vector into cell strains with known defects in repair or replication. In time, the quantitative and qualitative features of mutagenesis and toxicity of a wide array of DNA-damaging agents were profiled by this new technology.

This review examines in detail the application of a variety of experimental systems, primarily the use of site-specifically modified vector genomes, to categorize the mutagenic and toxic properties of DNA alkylating agents. Such agents are common environmental carcinogens, some are formed endogenously and cause spontaneous DNA damage and some have found use as cancer chemotherapeutic agents. The paper specifically reviews current knowledge of the biological properties of each of the lesions formed by low molecular weight alkylating agents. The structures of the relevant lesions are shown in Figure 3. By compiling data on lesion mutagenicity, genotoxicity and reparability, we develop a biological ‘fingerprint’ for each lesion (Table I). It is noteworthy that some lesions have mutagenicities at or approaching 100%, whereas others display comparatively weak mutagenic properties; however, it must be kept in mind that a lesion with a mutagenicity of only 0.1% creates mutations at a rate that is five orders of magnitude greater than the basal or spontaneous rate of mutagenesis. In the review, exocyclic monoadducts are covered first, followed by adducts in

Abbreviations: AAG, human 3-methyladenine-DNA glycosylase; AP site, apurinic site; BER, base excision repair; dAMP, deoxyadenosine monophosphate; dCMP, deoxycytidine monophosphate; dGMP, deoxyguanosine monophosphate; dNMP, deoxynucleoside monophosphate; dTTP, deoxythymidine triphosphate; EA, 1,N⁶-ethanoadenine; eA, 1,N⁶-ethenoadenine; eC, 3,N⁴-ethenocytosine; 1EtA, N1-ethyladenine; 3EtC, N3-ethylcytosine; Fapy, formamidopyrimidine; 1MeA, N1-methyladenine; 3MeA, N3-methyladenine; 7MeA, N7-methyladenine; 3MeC, N3-methylcytosine; 1MeG, N1-methylguanine; 3MeG, N3-methylguanine; 7MeG, N7-methylguanine; 8MeG, 8-methylguanine; MePT, methylphosphotriester; 3MeT, N3-methylthymine; MGMT, O⁶-methylguanine-DNA methyltransferase; MMR, mismatch repair; MMS, methylmethanesulfonate; MNNG, *N*-methyl-*N'*-nitro-*N*-nitrosoguanidine; MNU, *N*-methyl-*N*-nitrosourea; MGP, *N*-methylpurine-DNA glycosylase; NER, nucleotide excision repair; O⁶EtG, O⁶-ethylguanine; O⁶MeG, O⁶-methylguanine; O⁴MeT, O⁴-methylthymine; SAM, *S*-adenosylmethionine; TAG, 3-methyladenine-DNA glycosylase I.




Fig. 1. Pathways by which DNA-damaging agents induce biologically relevant events. Agents from the environment, chemically reactive natural species generated within cells and the misdirected action of natural intracellular enzymatic systems can result in the formation of a collection of DNA lesions (symbols attached to the helix). These lesions can be formal chemical-DNA adducts, such as *O*⁶MeG, which is a miscoding lesion during replication. They can be modifications of the sugar-phosphate backbone, such as MePT, which triggers a change in gene expression. They can be bases such as uracil, which can appear as the enzymatic deamination product of cytosine. Or, they can be lethal strand breaks, as would form after treatment of a cell with ionizing radiation or certain anticancer agents. Finding the relationships between the structures of each lesion and the biological endpoints of mutation, lethality and gene expression is the subject of this review.

which endocyclic atoms are the points of attachment to the alkyl residue. The final sections of the review cover small cyclic adducts. To keep the manuscript of a manageable size, we have limited our attention to adducts of one or two carbon residues, avoiding larger adducts and some of the lipid-derived adducts that have been reviewed elsewhere (6).

*O*⁶-methylguanine and *O*⁶-ethylguanine

*O*⁶-methylguanine (*O*⁶MeG), which causes G → A transitions (7), is the primary mutagenic lesion under most conditions of alkylation damage to the genome (8). *O*⁶MeG is formed from both endogenous (9,10) and exogenous sources (11), and studies have correlated its persistence to organ-specific tumorigenicity in rats (12). *O*⁶-ethylguanine (*O*⁶EtG) is the major mutagenic lesion formed by ethylating agents (13) and also primarily causes G → A transitions (14).

Escherichia coli has two *O*⁶MeG-DNA methyltransferases that can repair the adduct—the constitutive Ogt protein and the inducible Ada protein, which directly reverse methylation damage by transferring the alkyl group to one of the internal cysteine residues on each repair protein. This transfer irreversibly inactivates the repair proteins, making the non-enzymatic stoichiometric reaction ‘suicidal’ (15). Ada is part of the adaptive response, which was discovered when *E. coli* treated with a low dose of a methylating agent acquired resistance to the mutagenicity and toxicity of subsequent higher doses (16). The alkyl groups from *O*⁶AlkGua and *O*⁴AlkThy are transferred to Cys-321 at the C-terminus, whereas those from a third substrate, methylphosphotriester (MePT), is transferred to the N-terminus of Ada. It was initially believed that the methyl group from MePT was transferred to Cys-69 on the protein (17) but recent evidence identifies Cys-38 as the acceptor residue (18). Methylation of Cys-38 of Ada




Fig. 2. (A) Methods to evaluate the biological relevance of DNA damage. The ability of a DNA lesion (lollipop structure) to block polymerases *in vitro* and cause mispairing during DNA synthesis can be evaluated in a system in which a template containing the lesion is primed with a complementary oligonucleotide that terminates to the 3' side of the lesion. DNA synthesis may result in incorporation of non-complementary bases or in truncated products, which can be evaluated on sequencing gels. The same *in vitro* constructs, in double-stranded or single-stranded form, can also be used as substrates for DNA repair reactions using purified DNA repair proteins or cellular extracts. (B) To determine the mutagenic properties of the full population of adducts that form from treatment of DNA with a mutagen, a plasmid or viral vector is treated with the damaging agent. Replication of the vector in cells results in repair of some adducts but those that evade repair can possibly be converted into mutations. Sequencing the genomes of progeny can generate the mutational spectrum, which indicates the types and frequencies of specific mutations along the DNA sequence being studied. In parallel, one can map the locations of some of the DNA adducts by using enzymatic or chemical probes. The corresponding damage spectrum is often compared with the mutational spectrum in order to formulate hypotheses with regard to which DNA adduct might have caused specific mutations. (C) The most sophisticated system for analysis of mutagenesis involves chemical or enzymatic synthesis of an oligonucleotide that contains a candidate for mutagenesis (often the candidate is nominated based on the data from experiments shown in part B). The oligonucleotide is inserted into the genome of a virus or plasmid, which is later replicated within cells, either intra- or extra-chromosomally. Progeny are analyzed to determine the type, amount and genetic requirements for mutagenesis by the lesion. In parallel, the reduction in viable progeny is determined as an estimate of the extent to which each lesion inhibits replication of the genome.

converts it to a transcriptional activator of the genes encoding the ‘adaptive response’ to alkylating agents, namely, *ada*, *alkA*, *alkB* and *aidB*. This is the most nucleophilic of all available cysteine residues in Ada since it is not part of a network of hydrogen bonds. Methylation at this site reduces the overall negative charge on Ada. Reduction in charge density is important for the role of Ada as a transcription factor as it enhances its interaction with negatively charged DNA by 1000-fold (19). The number of Ada molecules is estimated to rise from one to two molecules in an unadapted state to ~3000 molecules in a fully adapted cell (20,21). It was initially found that Ada preferentially repairs *O*⁶MeG as compared with *O*⁴-methylthymine (*O*⁴MeT) (22) but recent evidence suggests that it repairs both lesions with equal efficiency (23).

The second DNA methyltransferase, Ogt, was discovered by deletion of the *ada* operon (24,25). Unlike Ada, Ogt is constitutively expressed in *E. coli*, shows a preference for repair of *O*⁴MeT and larger alkyl adducts and does not repair MePT (25). It is estimated that there are ~30 molecules of Ogt in wild-type *E. coli* (21). The mammalian homolog of Ogt and Ada is *O*⁶-methylguanine-DNA methyltransferase (MGMT) (also referred to as AGT). This enzyme works in




Fig. 3. Structures of DNA alkylation lesions.

a similar suicidal fashion but is not inducible, and it shows a 35-fold higher preference for repairing O^6 MeG over O^4 MeT (23). Human MGMT can be silenced by epigenetic modifications (26). This silencing plays a dual role in carcinogenesis as tumors not expressing MGMT acquire a mutator phenotype but also become more susceptible to killing by alkylating agents (27).

Ogt is speculated to provide protection at low levels of sporadic exposure to alkylating agents, whereas the adaptive response becomes more important against higher chronic exposures or acute exposures that trigger the transcriptional switch of the adaptive response operon. In addition to the methyltransferases, the UvrABC nucleotide excision repair (NER) pathway can also repair O^6 MeG. Excision of O^6 MeG on duplex substrates has been shown to occur *in vitro* (28) and *in vivo* (29). When O^6 MeG is present in a single-stranded context *in vivo*, NER does not affect mutation frequency of the lesion; the mutation frequencies in *E. coli* *uvrB⁺ada⁻ogt⁻* cells are very similar to those found in *uvrB⁻ada⁻ogt⁻* cells (30). Interestingly, Chambers *et al.* (31) found a 40-fold decrease in the G → A transition caused by an O^6 MeG lesion introduced on a single-stranded ΦX174 genome in an NER-deficient (*uvrA*) cell strain versus wild-type. The authors suggest a shielding mechanism by which UvrA binds to the lesion and protects it from repair by Ada or Ogt, leading to elevated mutation frequencies. There is some evidence of the NER pathway playing a role in repair of O^6 MeG in *Drosophila melanogaster* (32) and of O^6 EtG in *D. melanogaster* (33) and mammalian cells (34).

The mismatch repair (MMR) pathway has also been implicated in the cellular response to O^6 MeG (35). O^6 MeG can be processed by post-replicative MMR in *E. coli* in a double-stranded context, but in a single-stranded context (a gapped plasmid), the mutation frequencies in wild-type and *mutS⁻* cells are the same (36). Using an M13 single-stranded system containing an O^6 MeG lesion, Rye *et al.* (37) have shown that *dam⁻* and *mutH⁻* strains display the same mutation

frequency as wild-type, but *mutS⁻* and *mutL⁻* strains show a decrease. This result suggests that MMR proteins may aid in the repair of O^6 MeG in a cooperative fashion. Whereas early work suggested that O^6 EtG is not repaired by alkyltransferases or MMR in *E. coli* (38), more recent studies suggest that it is repaired by the same machinery that repairs O^6 MeG in mammalian cells (39). Nevertheless, in rat mammary cells, O^6 EtG is repaired 20 times faster than O^6 MeG by an unknown, MGMT-independent mechanism (40). In line with expectations based upon this finding, a G → A mutation is not seen as a frequent event at codon 12 of the *H-ras* gene in tumors initiated by *N*-ethyl-*N*-nitrosourea compared with tumors initiated by *N*-methyl-*N*-nitrosourea (MNU).

The toxicity of O^6 MeG has been established by several studies, and it appears that abortive MMR or inhibition of replication systems may play roles in converting the adduct into lethal intermediates. Evidence that O^6 MeG is potentially toxic in mammalian cells comes from a number of studies, including those in MGMT knockout mice, which display hypersensitivity to the lethal effects of alkylating agents that generate O^6 MeG (41). There are two proposed mechanisms by which this lesion contributes to the toxicity generated by alkylating agents. The first suggests that the lesion reduces the efficiency of replication by polymerases. This phenomenon has been studied using *in vitro* systems. The rates of replication by T4 and T5 phage DNA polymerases and *E. coli* polymerase I decrease linearly with increasing proportion of O^6 MeG in the synthetic oligonucleotide used as a template (42). Also, human polymerase β, subcloned in an *E. coli* plasmid, is blocked by O^6 MeG present on a single-stranded DNA template (43). The second mechanism leading to toxicity is that of futile cycling of the MMR system at an O^6 MeG:T pair (44,45). The model proposes recognition of this base pair by the MMR enzymes, which results in the removal of the newly incorporated thymine from the nascent strand opposite the lesion. On re-replication, O^6 MeG

Table I. Mutagenicity, genotoxicity and reparability of DNA alkylation lesions

Lesion	Mutagenic specificity	Genotoxicity	Repaired by prokaryotic enzymes/systems	Repaired by eukaryotic enzymes/systems
<i>O</i> ⁶ MeG	G → A	Toxic in presence of MMR	Ada, Ogt UvrABC (NER) MMR	MGMT NER MMR
<i>O</i> ⁶ EtG	G → A	Toxic in <i>Escherichia coli</i>	Not repaired by Ada or Ogt	MGMT NER MMR
<i>O</i> ² MeC <i>O</i> ² MeT <i>O</i> ⁴ MeT	T → C T → A in MMR-deficient cells	Possibly toxic Possibly toxic Toxic, but less than <i>O</i> ⁶ MeG and <i>O</i> ⁶ EtG in <i>E.coli</i>	Ada, Ogt	NER MGMT (minimal)
MePT	Not known	Not known	Ada	
1MeA	A → T	Mutagenic and toxic to <i>E.coli</i> in the absence of AlkB	AlkB	AAG ABH2, ABH3
1EtA		Mutagenic and toxic to <i>E.coli</i> in the absence of AlkB	AlkB	ABH2, ABH3
3MeA	A → T	Highly toxic	AlkA Tag UvrA	AAG/MPG
7MeA	Fapy-7MeA A → G			
1MeG	G → T G → A G → C	Mutagenic and toxic to <i>E.coli</i> in the absence of AlkB	AlkB	AAG
3MeG		Possibly toxic	AlkA Tag	
7MeG	Fapy-7MeG G → C G → T	Toxic via formation of AP sites and Fapy-7MeG	AlkA Fpg	AAG/ MPG hOGG1
3MeC	C → T C → A	Toxic	AlkB	AAG ABH2, ABH3
3EtC	C → T C → A	Toxic	AlkB	
3MeT	AlkB-deficient cell T → A T → C	Strong block to replication	Weak substrate for AlkB	FTO
8MeG	G → C		AlkA	Not repaired by known enzymes
eA	AlkB-deficient cell A → T A → G A → C	Mutagenic and toxic to <i>E.coli</i> in the absence of AlkB	AlkA AlkB	AAG
EA	A → T (weak) A → C (weak) A → G (weak)	Toxic to <i>E.coli</i> in the absence of AlkB	AlkB Weak substrate for AlkA	AAG
1,2-eG	G → T G → C	Mutagenic and causes frameshift		AAG, MUG
2,3-eG	G → A	Mutagenic	AlkA	
eC	C → A C → T	Mutagenic and toxic to <i>E.coli</i> in the absence of AlkB	AlkB dsUDG	hTDG

1,2-eG, 1,*N*²-Ethenoguanine; 2,3-eG, 3,*N*²-ethenoguanine; Fpg, formamidopyrimidine-DNA-glycosylase; FTO, Fat mass and obesity associated protein; *O*²MeC, *O*²-methylcytosine; *O*²MeT, *O*²-methylthymine.

preferentially pairs once again with an incoming thymine (7), reinitiating the repair and replication cycle. This persistent iteration of excision and synthesis is thought to result in a stabilized nick or small gap in one strand of DNA, which may activate damage signaling pathways (46). The recursive cycling mechanism is thought to be of practical significance in that it may explain the lethal effects of the anticancer drug, temozolomide (47). In *E.coli*, *O*⁶EtG is more toxic than *O*⁶MeG (38) but the mechanism underlying this differential toxicity is unknown.

*O*⁶MeG is known to be highly mutagenic. To study the mutations formed *in vivo*, Loechler *et al.* (7) constructed single-stranded M13mp8 DNA containing *O*⁶MeG at a specific position and transfected the same into *E.coli*. It was found that the predominant mutation generated by this lesion was a G → A transition. In wild-type *E.coli*, the lesion was weakly mutagenic, but challenging the Ada and Ogt repair systems of the cell by treatment with *N*-methyl-*N'*-nitro-*N*-nitrosoguanidine (MNNG; which forms alkyl adducts in the host genome) resulted in a robust, dose-dependent demonstration of the

mutagenic power of this adduct (7). This early study showed how significant even a few molecules per cell of a DNA repair protein could be as a protection against DNA damage. The ethyl homolog of $O^6\text{MeG}$, $O^6\text{EtG}$, introduced at a specific position in ΦX174 and transfected into *E.coli* produces higher mutation frequencies compared with $O^6\text{MeG}$ in the same system (48,49). $O^6\text{MeG}$ and $O^6\text{EtG}$ also have been site-specifically incorporated in Chinese hamster ovary cells and are shown to have a mutation frequency of 19 and 11%, respectively, in cells lacking O^6 -alkylguanine-DNA alkyltransferase (50).

A recent study used site-specific mutagenesis to generate single-stranded M13mp7 genomes containing $O^6\text{MeG}$ in all 16 possible permutations and combinations of nearest neighbor sequence contexts. These genomes were then introduced into *E.coli* mutants of different repair backgrounds and the mutation frequencies were determined by a novel and very sensitive assay. It was found that $O^6\text{MeG}$ went from being 10% mutagenic in repair-proficient cells to 100% mutagenic in repair-deficient cells (30). Moreover, it was found that DNA repair *in vivo* is sequence context dependent.

With regard to effects on gene expression, $O^6\text{MeG}$ can inhibit carbon-5 methylation of cytosines in 5'-deoxycytidine-deoxyguanosine-3' (dCpG) motifs by interfering with the binding of 5-methylcytosine DNA methyltransferases; eventually, this interference with natural methylation can lead to genome hypomethylation. The pairing of $O^6\text{MeG}$ with thymine can also lead to DNA hypomethylation (51). By these mechanisms, the formation of this adduct could affect the epigenetic program of mammalian cells.

*O*⁴-methylthymine

$O^4\text{MeT}$ is one of the mutagenic lesions formed concurrently with $O^6\text{MeG}$ when DNA is exposed to alkylating agents that react with DNA by an $\text{S}_{\text{N}}1$ mechanism. $O^4\text{MeT}$ is formed at a much lower level than $O^6\text{MeG}$, for example, the methylated thymine was detected at a level 126 times lower than that of $O^6\text{MeG}$ in calf thymus DNA treated with MNU (52). Although it is not an abundant lesion, $O^4\text{MeT}$ can be very mutagenic. Using site-specific mutagenesis tools, it was shown that $O^4\text{MeT}$ incorporated in single-stranded M13mp19 had a mutation frequency of 12% in repair-proficient *E.coli*. $O^6\text{MeG}$ gave a mutation frequency of <2% in the same repair-proficient system. Pre-treatment with MNGG to deplete or occupy endogenous repair enzymes doubled this mutation frequency (53). Similar results were obtained using double-stranded and gapped plasmids in *E.coli* (mutation frequency of 45% for $O^4\text{MeT}$ versus 6% for $O^6\text{MeG}$), leading to the conclusion that $O^4\text{MeT}$ is much more mutagenic than $O^6\text{MeG}$ (38) on a mole-per-mole basis under normal conditions of DNA repair proficiency in cells. $O^4\text{MeT}$ mimics cytosine in structure and generates an overwhelming majority of T → C transitions (54); it can also cause a small number of T → A transversions in MMR-deficient cells (39). $O^4\text{MeT}$ has been examined as a site-specific adduct in mammalian vectors and again appears to be more mutagenic than $O^6\text{MeG}$ in both repair-proficient and repair-deficient backgrounds (39,55). In *E.coli*, $O^4\text{MeT}$ is toxic but less so than $O^6\text{MeG}$ and $O^6\text{EtG}$ (38). $O^4\text{MeT}$ has been shown to be toxic to mammalian cells deficient in NER capability (56), suggesting a role for this repair pathway in the cellular defense against this adduct.

In *E.coli*, $O^4\text{MeT}$ is repaired by the same alkyltransferases that repair $O^6\text{MeG}$. The Ogt protein from *E.coli* seems to have a preference for repair of $O^4\text{MeT}$ over $O^6\text{MeG}$ (25). Ada repairs $O^6\text{MeG}$ and $O^4\text{MeT}$ with equal efficiency but human and rat alkyltransferases show a preference for $O^6\text{MeG}$ repair (23,57). Studies in mammalian cells have shown that the mutation frequency of $O^4\text{MeT}$ does not vary significantly in the presence or absence of alkyltransferase, indicating that it is probably not repaired by MGMT (39,55). In fact, mammalian alkyltransferases may actually inhibit repair of $O^4\text{MeT}$ by the NER pathway by binding to and shielding the lesion, as evidenced in *E.coli* in studies using plasmids expressing human and mouse methyltransferases (58). A study done in human cell lines using site-specifically modified plasmids containing $O^4\text{MeT}$ shows that repair is not influenced by the levels of alkyltransferase and that NER seems to be the most significant repair system for this lesion (56). With regard to

repair by MMR, one *in vitro* study found that *E.coli* MutS (a DNA MMR binding protein) does not bind to oligonucleotide duplexes containing a site-specifically incorporated $O^4\text{MeT}$:A base pair (35), whereas another shows that hMutS α , a protein of the MMR pathway in humans, recognizes and binds to a $O^4\text{MeT}$:A base pair quite well but very poorly to an $O^4\text{MeT}$:G base pair (59).

*O*²-methylcytosine and *O*²-methylthymine

O^2 -methylcytosine ($O^2\text{MeC}$) and O^2 -methylthymine ($O^2\text{MeT}$) are minor reaction products formed by treatment of DNA with alkylating agents such as MNU or MNGG. Both lesions are repaired *in vitro* by *E.coli* AlkA (60). $O^2\text{MeC}$ and $O^2\text{MeT}$ are predicted to interfere with minor groove contacts; yet, there have been very few studies of these modifications, making the lesions good candidates for future study.

Methylphosphotriester

Methylation damage can occur on the DNA sugar-phosphate backbone to form MePT. The physical accessibility and negative charge of the phosphate oxygens make them a favorable site for chemical reaction. When double-stranded DNA is treated with MNU, 17% of the total methylation occurs on the backbone to yield MePT (13). These adducts react with water and other nucleophiles much faster than the common diester form of phosphate linking adjacent nucleosides, leading to facile cleavage of the backbone. Of the two diastereomers formed, only the S_{p} -MePT is repaired by the Cys-38 residue in the N-terminal domain of Ada. This selective repair results because the oxygen atom on the phosphate in the S_{p} diastereomer is only 3.5Å away from the acceptor cysteine residue versus 5Å in the R_{p} configuration (18). As discussed earlier, N-terminal domain of Ada has an inherent electrostatic switch that works in a methylation-dependent fashion to modulate its affinity for DNA and ability to act as a transcription activator. There is no known homolog of N-terminal domain of Ada in eukaryotes, thus making the repair of MePT in mammalian cells uncertain.

In vivo studies using wild-type Ada and truncated Ada (lacking MePT repair capability) transfected into HeLa cells showed the same extent of resistance to the cytotoxic effects of alkylating agents, similar sister chromatid exchange induction, as well as host-cell reactivation of adenovirus (61). This observation suggests that MePT may not have cytotoxic effects in cells. The role of MePT seems to be a chemosensor for detection of methylation damage and induction of the adaptive response in *E.coli*, but their role, if any, in eukaryotes is unknown.

*N*1-methyladenine and *N*1-ethyladenine

*N*1-methyladenine (1MeA) is formed by alkylating agents mainly in single-stranded DNA and has been detected *in vitro* (62,63,64,65,66,67,68) and *in vivo* (64,69,70,71,72). $\text{S}_{\text{N}}2$ agents, such as methylmethanesulfonate (MMS) and the naturally occurring methyl halides, can generate 1MeA (15); similarly, the ethyl homolog, *N*1-ethyladenine (1EtA), is formed by ethylating agents both *in vitro* and *in vivo* (64). The preference for formation in single-stranded DNA is owed to location of the *N*1 atom of adenine at a site usually protected by base pairing in double-stranded DNA (73). 1MeA is cytotoxic because it disturbs DNA replication (15). 1-Methyldeoxyadenosine is known to be unstable due to a base-catalyzed Dimroth rearrangement, a complex mechanism, the net result of which is the migration of the *N*1 methyl group to the exocyclic *N*6 position of adenine (74).

A specialized DNA repair system protects cells from *N*1-substituted DNA lesions. The AlkB enzyme of the adaptive response repairs 1MeA both *in vitro* and *in vivo* (75) in an oxidative reaction that liberates formaldehyde from the methylated base, affording complete reversal of the damage. The role of AlkB in the repair of 1MeA seems to be the prevention of genotoxicity, because this very toxic adduct is only weakly mutagenic in cells. AlkB and its human homologs, ABH2 and ABH3, also repair 1EtA residues in DNA, with the release of acetaldehyde as the repair product (76). Studies of 1MeA *in vivo* reveal that the lesion severely blocks DNA replication, but the replication block can be partially overcome by the induction of SOS bypass polymerases. The 1MeA blockade is completely removed in

AlkB-proficient cells (75), underscoring the physiological relevance of the AlkB system for countering the toxicity of this base. While very toxic, as indicated above, 1MeA is at best weakly mutagenic. To the extent that it is mutagenic, 1MeA induces A to T mutations, which are enhanced following induction of the SOS polymerases. The base composition for A versus T was, respectively, 99 versus 0.61% in SOS⁻/AlkB⁻ cells, 99.7 versus 0.06% in SOS⁻/AlkB⁺ cells, and 98.6 versus 1.0% in SOS⁺/AlkB⁻ cells (75).

While the AlkB protein can repair the 1EtA lesion, it cannot repair 3-ethyladenine damage, which parallels AlkB's activity on 1MeA but not on 3-methyladenine (76). AlkB repairs 1EtA somewhat less well than 1MeA.

N3-methyladenine

N3-methyladenine (3MeA) can be formed in DNA by methylating agents as well as non-enzymatically by intracellular SAM. In a mammalian cell, SAM or some other methylating agent reacts with DNA to generate an estimated 600 3MeA per day (77). The half-life of 3MeA *in vivo* is estimated to be between 4–24 h (78). While 3MeA is not particularly mutagenic, it is a cytotoxic DNA lesion by virtue of its ability to block replication or by virtue of its ability to give rise to a chemically or enzymatically generated abasic/apurinic site (AP site). With regard to replication inhibition, it is thought that the methyl at the N3 position of purines sterically interferes with the required contact between the polymerase and minor groove on DNA (79). This property makes it essential for the cell to have in place defenses against this form of damage. 3MeA-DNA-glycosylases have evolved in both prokaryotic and eukaryotic systems to afford the efficient repair of this lesion. The prokaryotic system includes the highly selective and constitutive 3-methyladenine-DNA glycosylase I (TAG) protein and the inducible AlkA glycosylase with a broader specificity. The eukaryotic system is comprised of human 3MeA-DNA-glycosylase (AAG) and N-methylpurine-DNA glycosylase (MPG). AlkA and TAG repair 3MeA with equal efficiency on double-stranded DNA, but AlkA is 10- to 20-fold more efficient on single-stranded DNA (80). There is also evidence that UvrA, an ATPase and DNA-binding protein of the NER pathway, may be able to mitigate the cytotoxic effects of this lesion. One study used a neutral DNA equilibrium binding agent, Me-lex [*N*-methylpyrrololeucine dipeptide (lex) modified with an *O*-methyl sulfonate ester functionality], to introduce selectively 3MeA lesions in the minor groove of DNA. It was shown that this agent shows increasing toxicity to *E. coli* mutants lacking one base excision repair (BER) enzyme (AlkA), two BER enzymes (AlkA and TAG) or both BER and NER repair capabilities (AlkA, TAG and UvrA), in that order (81).

3MeA is not considered to be a seriously promutagenic lesion based upon work done in bacterial and in yeast systems. In 3MeA-DNA-glycosylase I (*tag*)-deficient *E. coli* mutants, treatment with MNU leads to a 5-fold increase in mutation frequency only under SOS-induced conditions. Furthermore, in repair-proficient cells, removal of 3MeA from the DNA does not show a significant difference in mutagenesis in SOS-induced versus SOS-uninduced cells (82). To study the mutational profile of 3MeA in eukaryotic cells, the p53 gene cDNA on a yeast expression vector was treated with Me-lex *in vitro* and transfected into a yeast strain containing the p53-dependent reporter ADE2 gene. The results show that Me-lex is a weak mutagen compared with MNU but that it induces A → T transversions as the most common genetic change (40% of all mutations) (83). Mutagenicity increased 2- to 3-fold in 3MeA-glycosylase-deficient strains, which suggests that the lesion driving the mutations is 3MeA (84). Interestingly, the methylated adenines in Me-lex-treated DNA give rise to mutations in a strictly sequence-specific manner.

The cytotoxicity of 3MeA is well established in the literature. *In vitro* studies showing chain termination one nucleotide 3' to adenines in methylated DNA templates pointed to 3MeA as a strong block to DNA replication. 3MeA in DNA has also been shown to be toxic in *E. coli* (81). Using Me-lex in combination with 3-methyladenine-DNA-glycosylase-proficient and -deficient cell lines, Engelward *et al.* (85) showed that 3MeA can cause p53 induction, S phase arrest,

sister chromatid exchange, chromosome aberrations and apoptosis in mammalian cells. As with N7-methylguanine (7MeG), enhanced repair of 3MeA by DNA-glycosylases of the BER pathway can lead to a flood of AP sites that can also contribute to mutations and lethality (86).

N7-methyladenine

N7-methyladenine (7MeA) is a minor lesion formed at a level 40-fold below that of 7MeG, which is typically the most abundant lesion in alkylated DNA (87). Like 7MeG, 7MeA possesses a cationic imidazole ring, which facilitates depurination and, alternatively, can favor hydrolysis of the five-membered ring to form the formamidopyrimidine (Fapy) derivative, Fapy-7MeA; this latter hydrolysis reaction is especially favored for the 7MeA in RNA (88), which has a stabilized glycosidic bond as compared with DNA. The half-life of 7MeA in DNA *in vivo* is only 2–3 hours, which is similar to its half-life *in vitro* at pH 7.2, 37°C (89). Fapy-7MeA is a mutagenic lesion displaying A → G transitions in single-stranded M13mp18 DNA transfected into SOS-induced *E. coli* (87,90). In these studies, dimethylsulfate-treated DNA was compared before and after treatment with alkali, which hydrolyzed the imidazole rings of N7-methylated adenines and guanines, forming the Fapy derivatives. Dimethylsulfate- and alkali-treated DNA was 60-fold more mutagenic than DNA treated with dimethylsulfate alone and showed mutations primarily at A:T sites.

N1-methylguanine

N1-methylguanine (1MeG) has been found both *in vitro* (67) and *in vivo* (91). With regard to biological relevance, the AlkB protein can repair 1MeG both *in vitro* and *in vivo* (75,92). The glycosylase AAG, which repairs 3MeA and a range of other lesions, is also active against 1MeG *in vitro* (93) but the *in vivo* relevance of AAG against this adduct has not been established as yet. 1MeG is a very strong block to replication, which can be partially overcome when the DNA lesion is partially repaired by AlkB; lesion bypass of 1MeG *in vivo* increases 8-fold from 2% in AlkB⁻ cells to 16% in AlkB⁺ cells. Similarly, AlkB causes a reduction in the mutagenicity of 1MeG from a very high frequency of 80% in AlkB⁻ cells to 4% in AlkB⁺ cells. Taken together, these data indicate that AlkB is a powerful protection against the mutagenic activity of this dangerous alkylated base. The mutational fingerprint of 1MeG reveals G → T (57% of all progeny), G → A (17%) and G → C (6%) mutations. In many instances, the induction of the SOS bypass polymerases results in increased bypass of a given lesion at the expense of reduced fidelity at the site of damage; however, the SOS polymerases are somewhat anti-mutagenic when they bypass this modified base (75).

N3-methylguanine

N3-methylguanine (3MeG) is thought to block replication in the same way as 3MeA does, but it is formed in DNA at a 15-fold lower level. The half-life of 3MeG *in vivo* has been shown to be 3–4 hours (89). It has been shown that *E. coli alkA* mutants are sensitive to alkylating agents even though they express Tag (94), which repairs 3MeA (a known cytotoxic lesion) as efficiently as AlkA on double-stranded DNA (80). This result suggests that 3MeG contributes to the toxic effects of alkylation seen in these cells.

Using cell extracts from adapted *E. coli*, it was shown that the AlkA protein can repair 3MeG present on methylated DNA *in vitro*. The same study also shows persistence of this adduct in unadapted *E. coli* 30 min after exposure to MNNG (95). A second *in vitro* study has shown that TAG also repairs 3MeG present on a synthetic G:C-rich double-stranded DNA sequence, albeit with an efficiency of only 1/70th that of AlkA (96).

N7-methylguanine and its degradation products

The N7 atom of guanine is the most chemically vulnerable site to attack by alkylating electrophiles as it has the highest negative electrostatic potential of all the other atoms within the DNA bases (97). This property also makes it a highly reactive ligand for metal ions such as platinum (98). When double-stranded DNA is treated with MMS or MNNG, 82 and 67% of the methylation occurs on the N7

position of guanine, respectively (13). Within the cell, 7MeG is produced at the rate of 4000 residues/human genome/day by the non-enzymatic reaction of SAM with DNA (77), and its steady-state level in repair-proficient cells is estimated to be 3000 bases (99). 7MeG has been detected in human DNA at the level of a few adducts per 10^7 bases (100). 7MeG by itself does not have any major mutagenic or cytotoxic effects. However, methylation at the N7 position destabilizes the *N*-glycosidic bond leading to spontaneous depurination of this lesion (101) and the resulting AP sites are toxic. AP sites can also be formed during repair of 7MeG by *N*-alkylpurine DNA-glycosylases, which are part of the BER pathway. Although not examined directly in the context of alkylation, the mutagenic and toxic properties of AP sites have been thoroughly investigated (86).

In addition to its role as a source of AP sites, 7MeG can manifest toxicity by converting to its imidazole ring-opened form. Hydrolysis of the imidazole ring of 7MeG forms 2,6-diamino-4-hydroxy-5*N*-methylformamidopyrimidine (Fapy-7MeG). Whereas this lesion does not cause mispairing with deoxyadenosine monophosphate (dAMP) or deoxythymidine monophosphate (dTTP), *in vitro* experiments using *E. coli* DNA polymerase I and poly[5'-deoxyguanosine-deoxycytidine-3' (dGpC)] templates (102) or Klenow fragment and M13mp18 template DNA (103) show that Fapy-7MeG blocks DNA chain elongation. Fapy-7MeG lesions present on M13mp18 phage template DNA also lead to a 2- to 3-fold increase in G → C and G → T transversions when transfected into SOS-induced *E. coli* (87). However, DNA polymerase I preferentially incorporates deoxycytidine monophosphate (dCMP) opposite Fapy-7MeG and a Fapy-7MeG:C pair is extended most efficiently compared with other possibilities. This property makes Fapy-7MeG a lesion with weak mutagenic potential (88).

In *E. coli*, AlkA is known to excise 7MeG from methylated DNA (95). In humans, this reaction is carried out by AAG/MPG (104). There exist specific DNA-glycosylases in *E. coli* [formamidopyrimidine-DNA-glycosylase (Fpg)] and mammalian cells [human 7,8-dihydro-8-oxoguanine DNA glycosylase (hOGG1)] (105) that remove Fapy-7MeG lesions. *Escherichia coli* Fpg repairs 7MeG very efficiently, with a K_m in the nanomolar range (88). It has been shown in a mammalian cell line by site-directed mutagenesis that over-expression of MPG sensitizes cells to alkylation damage by converting 7MeG into toxic AP sites, which lead to strand breaks. 7MeG by itself is not toxic to cells, nor is over-expression of MPG, but in combination, they can overwhelm the cell with AP sites leading to cytotoxicity. Rinne *et al.* (106) propose that these two aspects combined with appropriate delivery systems could be exploited for the selective targeting of tumor cells, thereby reducing the peripheral effects of DNA damage by drugs.

N3-methylcytosine and N3-ethylcytosine

N3-methylcytosine (3MeC) is formed by S_N2 agents such as MMS and the naturally occurring methyl halides (15) preferentially in single-stranded DNA. It has been detected both *in vitro* (62,64–68,107,108) and *in vivo* (64,70,71,91,108). The corresponding ethyl homolog, N3-ethylcytosine (3EtC), is formed by ethylating agents in single-stranded DNA and also has been detected *in vitro* (64,65) and *in vivo* (64,109). As with the 1-alkyladenines, these lesions probably exist only or predominantly in single-stranded DNA because this site of modification is normally protected by base pairing (73). 3MeC stalls DNA synthesis and is likely to be toxic (15).

In *E. coli*, the AlkB protein has good activity against 3MeC and 3EtC both *in vitro* and *in vivo* (62,63,75). The appreciable mutagenesis and toxicity of the 3-alkylcytosines *in vivo* is decimated by AlkB, although a portion of the toxicity can also be overcome by induction of the SOS bypass polymerases. With regard to mutagenic potential, if a cell has no AlkB and uninduced SOS bypass polymerases, 3MeC and 3EtC are 30% mutagenic, with the predominant mutations being C → T and C → A. Basal expression of AlkB of a few molecules per cell abrogates the mutagenicity of 3MeC and 3EtC, whereas expression of SOS bypass polymerases in the absence of AlkB increases the mutagenicity of both lesions to a striking 70%. Although investigations involving replication past 1MeA and 1MeG, which similarly have a blocked Watson–Crick

hydrogen bonding face, by DNA polymerases *in vitro* are lacking, it is known from *in vitro* studies that 3MeC inhibits replication by DNA polymerase I and does not cause mutation (107,110,111). However, some adduct bypass occurs with the incorporation of dAMP and dTMP opposite 3MeC (107). Therefore, the rules for misreplication of the 3-alkylcytosine lesions are the same both *in vitro* and *in vivo*, although the replicative system in cells is capable of a much higher mutation rate than is achieved *in vitro* (75,107).

N3-methylthymine

N3-methylthymine (3MeT) has been found both *in vitro* (64,65,67,68,112) and *in vivo* (112,113) and is formed through the reaction of DNA with S_N2 alkylating agents such as MMS. This adduct is a very weak substrate for AlkB, and it is a strong block to replication *in vivo*, which can be only slightly overcome by SOS bypass polymerase induction (75). Recently, fat mass obesity associated protein (FTO) has been shown as a 2-oxoglutarate-dependent demethylase for nucleic acid (114,115). FTO can efficiently repair 3MeT in single-stranded DNA but not in double-stranded DNA; it also shows strong activity on the demethylation of 3-methyluracil in single-stranded RNA (114,116). While there are numerous epidemiological studies associating the FTO gene with obesity, the biological basis for metabolic effects of this gene are still under investigation.

From the standpoint of its potential to induce genetic change, 3MeT is ~60% mutagenic in SOS⁻/AlkB⁻ cells, providing mostly T → A (47%) and T → C (9%) mutations. Studies performed *in vitro* also show that 3MeT is a strong block to the Klenow fragment of DNA polymerase I, which slightly increases deoxythymidine triphosphate (dTTP) incorporation on a poly(dC-d3MeT) template (117); interestingly, T is exclusively incorporated opposite the analogous 3-ethyldeoxythymidine adduct in one study (118), whereas A is exclusively incorporated in another (119).

8-Methylguanine

C8-alkylated DNA bases exist but have not been reported extensively in the literature. Recent studies have suggested that carbon-centered radicals can be a source of C8-alkylated lesions. 8-Methylguanine (8MeG) was shown to be produced *in vitro* in RNA (120) and DNA (121) by methyl radicals generated by oxidation of 1,2-dimethylhydrazine and methylhydrazine, respectively. Proof of *in vivo* DNA alkylation by carbon-centered radicals was given by Netto *et al.* (122) who detected 8MeG in DNA isolated from the liver and colon of rats administered 1,2-dimethylhydrazine. Other studies have shown that this lesion can also be produced *in vitro* and *in vivo* by genotoxic agents such as *tert*-butylhydroperoxide, diazoquinones and arenediazonium ions (123). These findings are significant as they suggest a possible contribution of 8MeG in the carcinogenic effects of these agents, especially 1,2-dimethylhydrazine, which induces adenocarcinomas of the colon in rodents.

Site-specific studies using 8MeG-containing oligonucleotides prepared by phosphoramidite synthesis have explored the mutagenicity and toxicity of this lesion. It was found that 8MeG on the template strand blocks *in vitro* extension of DNA by mammalian polymerase α , but not by the *E. coli* Klenow fragment (124). The products from the primer extension reaction were then analyzed for mutations. 8MeG was found to direct exo⁻ Klenow fragment-based incorporation of dCMP most of the time (77%) but also paired occasionally with deoxyguanosine monophosphate (dGMP) (1.1%) and dAMP (0.41%). Similar numbers were obtained for extension assays with mammalian polymerase α . Replication with the Klenow fragment also introduced small amounts of one (0.38%) and two (0.81%) base-pair deletions (124). These numbers mirror the thermodynamic stability of the 8MeG:deoxynucleoside monophosphate base (dNMP) pair, decreasing in the order dCMP > dGMP > dAMP >> dTMP. 1,2-Dimethylhydrazine induces both *O*⁶MeG and 8MeG in similar amounts in the DNA of rats (122). However, the mutation frequencies of 8MeG are two orders of magnitude less than those of *O*⁶MeG (125). Therefore, we may conclude that 8MeG is a weakly mutagenic lesion that in principle can contribute to G → C transversions in cells.

The repair of 8MeG has been studied *in vitro* by Gasparutto *et al.* (123). In this study, the authors incorporated 8MeG site specifically into oligonucleotides and probed the ability of bacterial, yeast and mammalian glycosylases to repair this lesion. Of the extensive list of enzymes evaluated, only AlkA was able to excise 8MeG. Human MPG did not repair 8MeG, nor did any of the glycosylases involved in repair of oxidative damage (Fpg, Nth of *E.coli*; Ntg1, Ntg2, Ogg1 of *Saccharomyces cerevisiae* and human Ogg1) (123).

8MeG has been shown to stabilize the Z-conformation of DNA in short oligonucleotides even in low salt concentrations. This property may be relevant *in vivo* as Z-DNA is thought to have a role in the regulation of DNA supercoiling (126). This lesion is also used as a chemical modification to stabilize quadruplex structures of G-rich sequences of DNA, which are proposed to have a role in telomeric DNA stability and in repression of transcription at the *c-myc* promoter (127). The wide range of potential biological activities of this lesion makes it a prime target for future investigations.

1,N⁶-ethenoadenine and 1,N⁶-ethanoadenine

The formation of 1,N⁶-ethenoadenine (eA) results from the reaction of adenine with products of unsaturated lipid peroxidation (128–131). This bifunctional DNA lesion arises endogenously under normal physiological conditions in both rodents and humans (132,133). Of great toxicological concern is the observation that eA is induced by common industrial agent vinyl chloride and its metabolites, such as chloroacetaldehyde. eA also occurs in chronically inflamed human and rodent tissues (134). Oxidative stress associated with inflammation is increasingly being linked to neurological disease, cancer promotion and accelerated aging (135).

In duplex DNA, eA can be repaired *in vitro* by glycosylases of the BER pathway (93,136). Mammalian cells can also repair etheno lesions by this route *in vivo* (137,138). Indeed, the BER enzyme AAG and its homologs are likely to be the primary vehicles of repair of eA in the duplex genomes of eukaryotes. In contrast, the *in vivo* repair of etheno adducts in *E.coli* was not clearly understood until recently; for example, one early study showed that neither BER nor NER figures prominently in etheno lesion repair (139). Early genetic studies on the mutagenicity of eA in *E.coli* reinforced this conundrum (140). The eA adduct was neither toxic nor mutagenic despite the fact that the base lacks any structural possibility of Watson–Crick complementarity. The issues raised in these studies were resolved in 2005 when biochemical studies provided the possibility that the direct reversal enzyme, AlkB, may play a significant role in the defense of cells against this type of bifunctional DNA damage. These biochemical studies showed that AlkB and its human homolog ABH3 can efficiently repair eA *in vitro* (141,142). AlkB uses a unique iron-mediated biochemical reaction involving α -ketoglutarate as a cofactor to putatively epoxidize the exocyclic double bond of eA. An epoxide may be hydrolyzed to a glycol with the glycol moiety being liberated as the dialdehyde, glyoxal. The direct reversal mechanism is also likely to be operative *in vivo*, as evidenced by genetic studies in which a single-stranded vector containing a single eA was replicated in AlkB-proficient and -deficient *E.coli* cells. In AlkB-deficient cells, eA is 35% mutagenic, yielding 25% A \rightarrow T, 5% A \rightarrow G and 5% A \rightarrow C mutations. SOS induction causes an increased incorporation of dAMP opposite to eA (141).

1,N⁶-ethanoadenine (EA) is the chemically reduced form of eA and forms through the reaction of adenine with the antitumor drug bis-chloroethylnitrosourea. EA can be weakly repaired by the *E.coli* enzyme AlkA (143) and the corresponding human enzyme AAG (93,144), which suggested that BER is a means of repair of this adduct. Recent work, however, by Frick *et al.* shows that the direct reversal repair enzyme AlkB easily alleviates the toxicity of EA in *E.coli* *in vivo* (145). In an AlkB-proficient cell, EA is almost non-toxic (i.e. easily bypassed) and not significantly mutagenic. However, in AlkB-deficient cells, EA is extremely toxic, showing an 86% reduction in replication. The adduct is weakly mutagenic causing A \rightarrow C (2%), A \rightarrow G (1%) and A \rightarrow T (1%) mutations (145).

1,N²-ethenoguanine and 3,N²-ethenoguanine

1,N²-ethenoguanine (1,2-eG) and its isomer 3,N²-ethenoguanine (2,3-eG) are cyclic DNA adducts formed, as with eA, by reagents such as chloroacetaldehyde (146) or 4-hydroperoxy-2-nonenal (147). Significantly, the former has been found in the liver DNA of rodents exposed to vinyl chloride (146). 1,2-eG can moderately block DNA polymerase and cause G \rightarrow T and G \rightarrow C base substitutions, as well as frameshift mutations (148). It can be repaired by mammalian uracil-DNA glycosylase (MUG) and AAG (93,149). In recent work, 1,2-eG was shown to be repaired, albeit weakly, by BER using a truncated form of the AAG enzyme (93). The AlkA protein can release 2,3-eG from DNA (150). The glycosidic bond of 2,3-eG is extremely labile, a property that has made assessment of biological significance of this modified base a difficult task (146). Nevertheless, Loeb and colleagues successfully determined the mutation frequency of the lesion to be \sim 13% in *E.coli*, where it primarily induces G \rightarrow A transitions.

3,N⁴-ethenocytosine

3,N⁴-ethenocytosine (eC) is produced from the same precursors and by the same pathways that generate eA in DNA (128–130,151). As with eA, the BER pathway ([human thymine-DNA-glycosylase (hTDG)] in human and [double-stranded uracil-DNA-glycosylase (dsUDG)] in *E.coli*) is an established strategy used by nature to suppress the biological effects of this adduct (137,151). The cellular defense network against eC additionally involves the AlkB pathway, at least in *E.coli*, which should be mechanistically similar to that of eA repair by AlkB (141). In *E.coli*, AlkB has a modest effect on eC toxicity but reduces the mutation rate of the adduct by about two-thirds from 82% in AlkB-deficient cells to 37% in AlkB-proficient hosts, implying incomplete conversion to cytosine prior to polymerase traversal. The mutations of eC in AlkB-deficient and -proficient cells are C \rightarrow A and C \rightarrow T, which are of approximately equal abundance in each cellular background.

Perspective

Thirty years ago, when *Carcinogenesis* was a new Journal, the field of cancer research looked very different from the way it looks today. The field was richly populated by chemists who identified carcinogens and studied the molecular transformations whereby those agents damaged DNA. The work described in this review started shortly after the Journal began when the complexities of DNA adduction confounded attempts to relate specific types of DNA damage with genetic changes that, presumably, attend the conversion of a normal cell into a fully malignant one. From that time to the present, much has been learned. Many oncogenes and tumor-suppressor genes have been discovered and placed like footsteps on the path between normalcy and malignancy (152). More recently, linkages have been made between the genetic events of oncogene activation and tumor-suppressor gene inactivation and parallel disruptions in biochemical networks. These studies are revealing the secrets of how cancer cells obtain the energy and the raw materials to finance their growth into a tumor (153,154). One revelation to come out of the last few decades is that the number of mutations in cancers is far in excess of the number one would expect on the basis of normal replication errors or perhaps even the enhanced rate of replication errors that occur when a polymerase tries to copy past a mutagenic DNA lesion such as those described in the manuscript. While it seems likely that genetic changes induced by carcinogens are an important step in the early stage of malignant transformation, it now seems clear that we need to find other chemical or biochemical events that underpin the ‘mutator phenotype’ of tumors (155). Answers may come from studies of virally induced diseases, such as human immunodeficiency virus and hepatitis, where recent work has discovered enzymatic DNA-targeted base deamination systems that cause a high density of mutations within a genome (156). Answers might also come from the field of immunology where enzymes such as activation-induced deaminase cause, once again, a high density of mutations in a localized stretch of DNA (157,158).

One of the most important contributions of work on the chemical biology of mutagenesis has been the collateral impact of this field on the nearby field of DNA repair. It is now common for workers in the repair field to use oligonucleotides with single lesions, originally made for studies of mutagenesis, to characterize the detailed biochemical mechanisms by which repair enzymes or complexes reverse the damage. Moreover, studies of mutagenesis done using cells that are defective in a specific repair enzyme (141) or that express specialized polymerases (159) have provided high-quality data that have established the physiological relevance of specific enzymes as protectors from damage or as the vehicles by which damage is processed into events with disastrous consequences for the cell and organism.

Looking ahead, there is much to do. To give one example, the process of inflammation is clearly associated with cancer development (135). The range of DNA damages created by inflammation-generated reactive oxygen and nitrogen species is vast, and the task will be a large one to determine how each of these lesions contributes to the biological endpoints downstream of an inflammatory event. As a second example, workers will soon develop modified versions of the tools described herein to probe what may become a new field ... RNA repair. Some mRNA species are so long that it takes a day to transcribe them (160–162). These important molecules not only need to have their informational integrity protected but also the energy used in their synthesis is large and would be wasted if a single lesion, for example, an eA residue, made them unreadable. Finally, while this review focuses on only one class of lesion, the small alkylated bases, it illustrates how much can be learned about the chemical rules of mutagenesis. Ten years ago, studies of the mutagenic properties of 5-hydroxycytosine (163), which induces C to T transitions, were the starting point for a novel application in the development of anti-viral agents (164). It is expected that additional examples of this nature, in which basic studies of mutagenesis drive clinical development, will help propel this field into a robust future.

Funding

National Institutes of Health (CA080024, CA26731, ES02109).

Acknowledgements

We thank James C. Delaney and Bogdan Fedeles for editorial and artistic contributions.

Conflict of Interest Statement: None declared.

References

- Loeb, L.A. *et al.* (2008) Advances in chemical carcinogenesis: a historical review and prospective. *Cancer Res.*, **68**, 6863–6872.
- Conticello, S. (2008) The AID/APOBEC family of nucleic acid mutators. *Genome Biol.*, **9**, 229.
- Basu, A.K. *et al.* (1988) Site-specifically modified oligodeoxynucleotides as probes for the structural and biological effects of DNA-damaging agents. *Chem. Res. Toxicol.*, **1**, 1–18.
- Groopman, J.D. *et al.* (2008) Protective interventions to prevent aflatoxin-induced carcinogenesis in developing countries. *Annu. Rev. Public Health*, **29**, 187–203.
- Essigmann, J.M. *et al.* (1983) Interactions of aflatoxin B1 and alkylating agents with DNA: structural and functional studies. *Cold Spring Harb. Symp. Quant. Biol.*, **47**, 327–337.
- West, J.D. *et al.* (2006) Endogenous reactive intermediates as modulators of cell signaling and cell death. *Chem. Res. Toxicol.*, **19**, 173–194.
- Loechler, E.L. *et al.* (1984) *In vivo* mutagenesis by *O*⁶-methylguanine built into a unique site in a viral genome. *Proc. Natl Acad. Sci. USA*, **81**, 6271–6275.
- Lindahl, T. *et al.* (1988) Regulation and expression of the adaptive response to alkylating agents. *Annu. Rev. Biochem.*, **57**, 133–157.
- Taverna, P. *et al.* (1996) Generation of an endogenous DNA-methylating agent by nitrosation in *Escherichia coli*. *J. Bacteriol.*, **178**, 5105–5111.
- Shuker, D.E.G. *et al.* (1997) Nitrosated glycine derivatives as a potential source of *O*⁶-methylguanine in DNA. *Cancer Res.*, **57**, 366–369.
- Loveless, A. (1969) Possible relevance of *O*⁶-alkylation of deoxyguanosine to the mutagenicity and carcinogenicity of nitrosamines and nitrosamides. *Nature*, **223**, 206–207.
- Margison, G.P. *et al.* (1975) Chemical carcinogenesis in the nervous system. Preferential accumulation of *O*⁶-methylguanine in rat brain deoxyribonucleic acid during repetitive administration of *N*-methyl-*N*-nitrosourea. *Biochem. J.*, **148**, 521–530.
- Beranek, D.T. (1990) Distribution of methyl and ethyl adducts following alkylation with monofunctional alkylating agents. *Mutat. Res.*, **231**, 11–30.
- Engelbergs, J. *et al.* (2000) Role of DNA repair in carcinogen-induced ras mutation. *Mutat. Res.*, **450**, 139–153.
- Sedgwick, B. (2004) Repairing DNA-methylation damage. *Nat. Rev. Mol. Cell Biol.*, **5**, 148–157.
- Samson, L. *et al.* (1977) A new pathway for DNA repair in *Escherichia coli*. *Nature*, **267**, 281–283.
- Sedgwick, B. *et al.* (1988) Functional domains and methyl acceptor sites of the *Escherichia coli* Ada protein. *J. Biol. Chem.*, **263**, 4430–4433.
- He, C. *et al.* (2005) A methylation-dependent electrostatic switch controls DNA repair and transcriptional activation by *E. coli* Ada. *Mol. Cell*, **20**, 117–129.
- Myers, L.C. *et al.* (1995) Metal dependence of transcriptional switching in *Escherichia coli* Ada. *J. Biol. Chem.*, **270**, 6664–6670.
- Mitra, S. *et al.* (1982) *O*⁶-methylguanine-DNA methyltransferase in wild-type and *ada* mutants of *Escherichia coli*. *J. Bacteriol.*, **152**, 534–537.
- Rebeck, G.W. *et al.* (1989) Characterization of the major DNA repair methyltransferase activity in unadapted *Escherichia coli* and identification of a similar activity in *Salmonella typhimurium*. *J. Bacteriol.*, **171**, 4563–4568.
- Sassanfar, M. *et al.* (1991) Relative efficiencies of the bacterial, yeast, and human DNA methyltransferases for the repair of *O*⁶-methylguanine and *O*⁴-methylthymine. Suggestive evidence for *O*⁴-methylthymine repair by eukaryotic methyltransferases. *J. Biol. Chem.*, **266**, 2767–2771.
- Paalman, S.R. *et al.* (1997) Specificity of DNA repair methyltransferases determined by competitive inactivation with oligonucleotide substrates: evidence that *Escherichia coli* Ada repairs *O*⁶-methylguanine and *O*⁴-methylthymine with similar efficiency. *Biochemistry*, **36**, 11118–11124.
- Rebeck, G.W. *et al.* (1988) A second DNA methyltransferase repair enzyme in *Escherichia coli*. *Proc. Natl Acad. Sci. USA*, **85**, 3039–3043.
- Potter, P.M. *et al.* (1987) Characterisation and nucleotide sequence of *ogt*, the *O*⁶-alkylguanine-DNA-alkyltransferase gene of *E. coli*. *Nucleic Acids Res.*, **15**, 9177–9193.
- Esteller, M. *et al.* (2000) Inactivation of the DNA repair gene *O*⁶-methylguanine-DNA methyltransferase by promoter hypermethylation is associated with G to A mutations in *K-ras* in colorectal tumorigenesis. *Cancer Res.*, **60**, 2368–2371.
- Esteller, M. *et al.* (2004) Generating mutations but providing chemosensitivity: the role of *O*⁶-methylguanine DNA methyltransferase in human cancer. *Oncogene*, **23**, 1–8.
- Voigt, J.M. *et al.* (1989) Repair of *O*⁶-methylguanine by ABC excinuclease of *Escherichia coli* *in vitro*. *J. Biol. Chem.*, **264**, 5172–5176.
- Samson, L. *et al.* (1988) Alternative pathways for the *in vivo* repair of *O*⁶-alkylguanine and *O*⁴-alkylthymine in *Escherichia coli*: the adaptive response and nucleotide excision repair. *EMBO J.*, **7**, 2261–2267.
- Delaney, J.C. *et al.* (2001) Effect of sequence context on *O*⁶-methylguanine repair and replication *in vivo*. *Biochemistry*, **40**, 14968–14975.
- Chambers, R.W. *et al.* (1985) *uvrA* and *recA* mutations inhibit a site-specific transition produced by a single *O*⁶-methylguanine in gene G of bacteriophage ΦX174. *Proc. Natl Acad. Sci. USA*, **82**, 7173–7177.
- Nivard, M.J. *et al.* (1996) Mutational spectra induced under distinct excision repair conditions by the 3 methylating agents *N*-methyl-*N*-nitrosourea, *N*-methyl-*N*-nitro-*N*-nitrosoguanidine and *N*-nitrosodimethylamine in postmeiotic male germ cells of *Drosophila*. *Mutat. Res.*, **352**, 97–115.
- Tosal, L. *et al.* (2001) *In vivo* repair of ENU-induced oxygen alkylation damage by the nucleotide excision repair mechanism in *Drosophila melanogaster*. *Mol. Genet. Genomics*, **265**, 327–335.
- Bronstein, S.M. *et al.* (1992) Efficient repair of *O*⁶-ethylguanine, but not *O*⁴-ethylthymine or *O*²-ethylthymine, is dependent upon *O*⁶-alkylguanine-DNA alkyltransferase and nucleotide excision repair activities in human cells. *Cancer Res.*, **52**, 2008–2011.
- Rasmussen, L.J. *et al.* (1996) The *Escherichia coli* MutS DNA mismatch binding protein specifically binds *O*⁶-methylguanine DNA lesions. *Carcinogenesis*, **17**, 2085–2088.
- Pauly, G.T. *et al.* (1995) Mutagenesis in *Escherichia coli* by three *O*⁶-substituted guanines in double-stranded or gapped plasmids. *Biochemistry*, **34**, 8924–8930.
- Rye, P.T. *et al.* (2008) Mismatch repair proteins collaborate with methyltransferases in the repair of *O*⁶-methylguanine. *DNA Repair (Amst.)*, **7**, 170–176.

38. Pauly,G.T. *et al.* (1998) Comparison of mutagenesis by *O*⁶-methyl- and *O*⁶-ethylguanine and *O*⁴-methylthymine in *Escherichia coli* using double-stranded and gapped plasmids. *Carcinogenesis*, **19**, 457–461.
39. Pauly,G.T. *et al.* (2001) Mutagenesis by *O*⁶-methyl-, *O*⁶-ethyl-, and *O*⁶-benzylguanine and *O*⁴-methylthymine in human cells: effects of *O*⁶-alkyl guanine-DNA alkyltransferase and mismatch repair. *Chem. Res. Toxicol.*, **14**, 894–900.
40. Engelbergs,J. *et al.* (1998) Fast repair of *O*⁶-ethylguanine, but not *O*⁶-methylguanine, in transcribed genes prevents mutation of *H-ras* in rat mammary tumorigenesis induced by ethylnitrosourea in place of methyl-nitrosourea. *Proc. Natl Acad. Sci. USA*, **95**, 1635–1640.
41. Glassner,B.J. *et al.* (1999) DNA repair methyltransferase (Mgmt) knock-out mice are sensitive to the lethal effects of chemotherapeutic alkylating agents. *Mutagenesis*, **14**, 339–347.
42. Snow,E.T. *et al.* (1984) Base-pairing properties of *O*⁶-methylguanine in template DNA during *in vitro* DNA replication. *J. Biol. Chem.*, **259**, 8095–8100.
43. Abbotts,J. *et al.* (1988) Expression of human DNA polymerase β in *Escherichia coli* and characterization of the recombinant enzyme. *Biochemistry*, **27**, 901–909.
44. Karran,P. *et al.* (1982) Mismatch correction at *O*⁶-methylguanine residues in *E. coli* DNA. *Nature*, **296**, 868–869.
45. Goldmacher,V.S. *et al.* (1986) Isolation and partial characterization of human cell mutants differing in sensitivity to killing and mutation by methylnitrosourea and *N*-methyl-*N'*-nitro-*N*-nitrosoguanidine. *J. Biol. Chem.*, **261**, 12462–12471.
46. York,S.J. *et al.* (2006) Mismatch repair-dependent iterative excision at irreparable *O*⁶-methylguanine lesions in human nuclear extracts. *J. Biol. Chem.*, **281**, 22674–22683.
47. Newlands,E.S. *et al.* (1997) Temozolomide: a review of its discovery, chemical properties, pre-clinical development and clinical trials. *Cancer Treat. Rev.*, **23**, 35–61.
48. Chambers,R.W. (1991) Site-specific mutagenesis in cells with normal DNA repair systems: transitions produced from DNA carrying a single *O*⁶-alkylguanine. *Nucleic Acids Res.*, **19**, 2485–2488.
49. Chambers,R.W. (1993) Site-directed mutagenesis in single cells: transitions produced by DNA carrying a single *O*⁶-alkylguanine residue. *Mutat. Res.*, **299**, 123–133.
50. Ellison,K.S. *et al.* (1989) Site-specific mutagenesis by *O*⁶-alkylguanines located in the chromosomes of mammalian cells: influence of the mammalian *O*⁶-alkylguanine-DNA alkyltransferase. *Proc. Natl Acad. Sci. USA*, **86**, 8620–8624.
51. Franco,R. *et al.* (2008) Oxidative stress, DNA methylation and carcinogenesis. *Cancer Lett.*, **266**, 6–11.
52. Dolan,M.E. *et al.* (1985) Extent of formation of *O*⁴-methylthymidine in calf thymus DNA methylated by *N*-methyl-*N*-nitrosourea and lack of repair of this product by rat liver *O*⁶-alkylguanine-DNA-alkyltransferase. *Carcinogenesis*, **6**, 1611–1614.
53. Dosanjh,M.K. *et al.* (1991) Comparative mutagenesis of *O*⁶-methylguanine and *O*⁴-methylthymine in *Escherichia coli*. *Biochemistry*, **30**, 7027–7033.
54. Preston,B.D. *et al.* (1986) Mutagenic potential of *O*⁴-methylthymine *in vivo* determined by an enzymatic approach to site-specific mutagenesis. *Proc. Natl Acad. Sci. USA*, **83**, 8501–8505.
55. Altshuler,K.B. *et al.* (1996) Intrachromosomal probes for mutagenesis by alkylated DNA bases replicated in mammalian cells: a comparison of the mutagenicities of *O*⁴-methylthymine and *O*⁶-methylguanine in cells with different DNA repair backgrounds. *Chem. Res. Toxicol.*, **9**, 980–987.
56. Klein,J.C. *et al.* (1994) Role of nucleotide excision repair in processing of *O*⁴-alkylthymines in human cells. *J. Biol. Chem.*, **269**, 25521–25528.
57. Zak,P. *et al.* (1994) Repair of *O*⁶-methylguanine and *O*⁴-methylthymine by the human and rat *O*⁶-methylguanine-DNA methyltransferases. *J. Biol. Chem.*, **269**, 730–733.
58. Samson,L. *et al.* (1997) Mammalian DNA repair methyltransferases shield *O*⁶MeT from nucleotide excision repair. *Carcinogenesis*, **18**, 919–924.
59. Duckett,D.R. *et al.* (1996) Human MutS α recognizes damaged DNA base pairs containing *O*⁶-methylguanine, *O*⁴-methylthymine, or the cisplatin-(GpG) adduct. *Proc. Natl Acad. Sci. USA*, **93**, 6443–6447.
60. McCarthy,T.V. *et al.* (1984) Inducible repair of *O*-alkylated DNA pyrimidines in *Escherichia coli*. *EMBO J.*, **3**, 545–550.
61. Ishizaki,K. *et al.* (1987) Expression of the truncated *E. coli* *O*⁶-methylguanine methyltransferase gene in repair-deficient human cells and restoration of cellular resistance to alkylating agents. *Mutat. Res.*, **184**, 121–128.
62. Trewick,S.C. *et al.* (2002) Oxidative demethylation by *Escherichia coli* AlkB directly reverts DNA base damage. *Nature*, **419**, 174–178.
63. Falnes,P.O. *et al.* (2002) AlkB-mediated oxidative demethylation reverses DNA damage in *Escherichia coli*. *Nature*, **419**, 178–182.
64. Singer,B. *et al.* (1983) *Molecular Biology of Mutagens and Carcinogens*. Plenum, New York.
65. Beranek,D.T. *et al.* (1980) A comprehensive quantitative analysis of methylated and ethylated DNA using high pressure liquid chromatography. *Carcinogenesis*, **1**, 595–606.
66. Gomes,J.D. *et al.* (1983) Reverse-phase high-performance liquid chromatography of chemically modified DNA. *Anal. Biochem.*, **129**, 387–391.
67. Chang,C.J. *et al.* (1983) Chemical modification of deoxyribonucleic acids: a direct study by carbon-13 nuclear magnetic resonance spectroscopy. *J. Org. Chem.*, **48**, 5151–5160.
68. Ashworth,D.J. *et al.* (1985) Chemical modification of nucleic acids. Methylation of calf thymus DNA investigated by mass spectrometry and liquid chromatography. *Biomed. Mass Spectrom.*, **12**, 309–318.
69. Margison,G.P. *et al.* (1976) Methylated purines in the deoxyribonucleic acid of various Syrian-golden-hamster tissues after administration of a hepatocarcinogenic dose of dimethylnitrosamine. *Biochem. J.*, **157**, 627–634.
70. Faustman,E.M. *et al.* (1980) A method for the rapid quantitation of methylated hepatic DNA-purines using high pressure liquid chromatography. *J. Pharmacol. Methods*, **4**, 305–312.
71. Beranek,D.T. *et al.* (1983) Correlation between specific DNA-methylation products and mutation induction at the HGPRT locus in Chinese hamster ovary cells. *Mutat. Res.*, **110**, 171–180.
72. Faustman-Watts,E.M. *et al.* (1984) DNA-purine methylation in hepatic chromatin following exposure to dimethylnitrosamine or methylnitrosourea. *Biochem. Pharmacol.*, **33**, 585–590.
73. Bodell,W.J. *et al.* (1979) Influence of hydrogen bonding in DNA and polynucleotides on reaction of nitrogens and oxygens toward ethylnitrosourea. *Biochemistry*, **18**, 2860–2863.
74. Engel,J.D. (1975) Mechanism of the Dimroth rearrangement in adenosine. *Biochem. Biophys. Res. Commun.*, **64**, 581–586.
75. Delaney,J.C. *et al.* (2004) Mutagenesis, genotoxicity, and repair of 1-methyladenine, 3-alkylcytosines, 1-methylguanine, and 3-methylthymine in *alkB* *Escherichia coli*. *Proc. Natl Acad. Sci. USA*, **101**, 14051–14056.
76. Duncan,T. *et al.* (2002) Reversal of DNA alkylation damage by two human dioxygenases. *Proc. Natl Acad. Sci. USA*, **99**, 16660–16665.
77. Rydberg,B. *et al.* (1982) Nonenzymatic methylation of DNA by the intracellular methyl group donor S-adenosyl-L-methionine is a potentially mutagenic reaction. *EMBO J.*, **1**, 211–216.
78. Singer,B. (1979) N-nitroso alkylating agents: formation and persistence of alkyl derivatives in mammalian nucleic acids as contributing factors in carcinogenesis. *J. Natl Cancer Inst.*, **62**, 1329–1339.
79. Fronza,G. *et al.* (2004) The biological effects of N3-methyladenine. *J. Cell. Biochem.*, **91**, 250–257.
80. Bjelland,S. *et al.* (1996) Different efficiencies of the Tag and AlkA DNA glycosylases from *Escherichia coli* in the removal of 3-methyladenine from single-stranded DNA. *FEBS Lett.*, **397**, 127–129.
81. Shah,D. *et al.* (2001) Evidence in *Escherichia coli* that N3-methyladenine lesions induced by a minor groove binding methyl sulfonate ester can be processed by both base and nucleotide excision repair. *Biochemistry*, **40**, 1796–1803.
82. Chaudhuri,I. *et al.* (1991) 3-Methyladenine mutagenesis under conditions of SOS induction in *Escherichia coli*. *Carcinogenesis*, **12**, 2283–2289.
83. Kelly,J.D. *et al.* (1999) Relationship between DNA methylation and mutational patterns induced by a sequence selective minor groove methylating agent. *J. Biol. Chem.*, **274**, 18327–18334.
84. Monti,P. *et al.* (2002) Influences of base excision repair defects on the lethality and mutagenicity induced by Me-lex, a sequence-selective N3-adenine methylating agent. *J. Biol. Chem.*, **277**, 28663–28668.
85. Engelward,B.P. *et al.* (1998) A chemical and genetic approach together define the biological consequences of 3-methyladenine lesions in the mammalian genome. *J. Biol. Chem.*, **273**, 5412–5418.
86. Fortini,P. *et al.* (2003) The base excision repair: mechanisms and its relevance for cancer susceptibility. *Biochimie*, **85**, 1053–1071.
87. Tudek,B. *et al.* (1999) Mutagenic specificity of imidazole ring-opened 7-methylpurines in M13mp18 phage DNA. *Acta Biochim. Pol.*, **46**, 785–799.
88. Tudek,B. (2003) Imidazole ring-opened DNA purines and their biological significance. *J. Biochem. Mol. Biol.*, **36**, 12–19.
89. Lawley,P.D. *et al.* (1976) Removal of minor methylation products 7-methyladenine and 3-methylguanine from DNA of *Escherichia coli* treated with dimethyl sulphate. *Chem. Biol. Interact.*, **12**, 211–220.
90. Tudek,B. *et al.* (1992) Biological properties of imidazole ring-opened N7-methylguanine in M13mp18 phage DNA. *Nucleic Acids Res.*, **20**, 3079–3084.

91. Culp, L.A. *et al.* (1970) Methylated bases in DNA of animal origin. *Arch. Biochem. Biophys.*, **136**, 73–79.
92. Falnes, P.O. (2004) Repair of 3-methylthymine and 1-methylguanine lesions by bacterial and human AlkB proteins. *Nucleic Acids Res.*, **32**, 6260–6267.
93. Lee, C.Y. *et al.* (2009) Recognition and processing of a new repertoire of DNA substrates by human 3-methyladenine DNA glycosylase (AAG). *Biochemistry*, **48**, 1850–1861.
94. Evensen, G. *et al.* (1982) Adaptation to alkylation resistance involves the induction of a DNA glycosylase. *Nature*, **296**, 773–775.
95. Karran, P. *et al.* (1982) Induction of a DNA glycosylase for N-methylated purines is part of the adaptive response to alkylating agents. *Nature*, **296**, 770–773.
96. Bjelland, S. *et al.* (1993) Excision of 3-methylguanine from alkylated DNA by 3-methyladenine DNA glycosylase I of *Escherichia coli*. *Nucleic Acids Res.*, **21**, 2045–2049.
97. Pullman, A. *et al.* (1981) Molecular electrostatic potential of the nucleic acids. *Q. Rev. Biophys.*, **14**, 289–380.
98. Jamieson, E.R. *et al.* (1999) Structure, recognition, and processing of cisplatin-DNA adducts. *Chem. Rev.*, **99**, 2467–2498.
99. Kunkel, T.A. (1999) The high cost of living. *Trends Genet.*, **15**, 93–94.
100. Szyf, K. *et al.* (1996) Tobacco smoke-associated N7-alkylguanine in DNA of larynx tissue and leucocytes. *Carcinogenesis*, **17**, 501–506.
101. Saffhill, R. *et al.* (1985) Mechanisms of carcinogenesis induced by alkylating agents. *Biochim. Biophys. Acta*, **823**, 111–145.
102. Boiteux, S. *et al.* (1983) Imidazole open ring 7-methylguanine: an inhibitor of DNA synthesis. *Biochem. Biophys. Res. Commun.*, **110**, 552–558.
103. O'Connor, T.R. *et al.* (1988) Ring-opened 7-methylguanine residues in DNA are a block to *in vitro* DNA synthesis. *Nucleic Acids Res.*, **16**, 5879–5894.
104. O'Connor, T.R. (1993) Purification and characterization of human 3-methyladenine-DNA glycosylase. *Nucleic Acids Res.*, **21**, 5561–5569.
105. Asagoshi, K. *et al.* (2000) Enzymatic properties of *Escherichia coli* and human 7,8-dihydro-8-oxoguanine DNA glycosylases. *Nucleic Acids Symp. Ser.*, **44**, 11–12.
106. Rinne, M.L. *et al.* (2005) N-methylpurine DNA glycosylase overexpression increases alkylation sensitivity by rapidly removing non-toxic 7-methylguanine adducts. *Nucleic Acids Res.*, **33**, 2859–2867.
107. Boiteux, S. *et al.* (1982) Mutagenesis by alkylating agents: coding properties for DNA polymerase of poly (dC) template containing 3-methyl cytosine. *Biochimie*, **64**, 637–641.
108. Kawasaki, H. *et al.* (1985) High-performance liquid chromatographic determination of 3-methylcytosine in deoxyribonucleic acid treated with carcinogenic methylating agents *in vitro* and *in vivo*. *Chem. Pharm. Bull.*, **33**, 1170–1174.
109. Frei, J.V. *et al.* (1978) Alkylation of deoxyribonucleic acid *in vivo* in various organs of C57BL mice by the carcinogens N-methyl-N-nitrosourea, N-ethyl-N-nitrosourea and ethylmethanesulphonate in relation to induction of thymic lymphoma. Some applications of high-pressure liquid chromatography. *Biochem. J.*, **174**, 1031–1044.
110. Abbott, P.J. *et al.* (1979) DNA synthesis with methylated poly(dC-dG) templates. Evidence for a competitive nature to miscoding by O⁶-methylguanine. *Biochim. Biophys. Acta*, **562**, 51–61.
111. Saffhill, R. (1984) Differences in the promutagenic nature of 3-methylcytosine as revealed by DNA and RNA polymerising enzymes. *Carcinogenesis*, **5**, 691–693.
112. Den, E.L. *et al.* (1986) Formation and stability of alkylated pyrimidines and purines (including imidazole ring-opened 7-alkylguanine) and alkylphosphotriesters in liver DNA of adult rats treated with ethylnitrosourea or dimethylnitrosamine. *Carcinogenesis*, **7**, 393–403.
113. Singer, B. *et al.* (1983) *Escherichia coli* polymerase I can use O²-methyl deoxythymidine or O²-methyldeoxythymidine in place of deoxythymidine in primed poly(dA-dT).poly(dA-dT) synthesis. *Proc. Natl Acad. Sci. USA*, **80**, 4884–4888.
114. Gerken, T. *et al.* (2007) The obesity-associated FTO gene encodes a 2-oxoglutarate-dependent nucleic acid demethylase. *Science*, **318**, 1469–1472.
115. Yi, C. *et al.* (2009) A non-heme iron-mediated chemical demethylation in DNA and RNA. *Acc. Chem. Res.*, **42**, 519–529.
116. Jia, G. *et al.* (2008) Oxidative demethylation of 3-methylthymine and 3-methyluracil in single-stranded DNA and RNA by mouse and human FTO. *FEBS Lett.*, **582**, 3313–3319.
117. Huff, A.C. *et al.* (1987) DNA damage at thymine N-3 abolishes base-pairing capacity during DNA synthesis. *J. Biol. Chem.*, **262**, 12843–12850.
118. Grevatt, P.C. *et al.* (1991) The role of N3-ethyldeoxythymidine in mutagenesis and cytotoxicity by ethylating agents. *J. Biol. Chem.*, **266**, 1269–1275.
119. Bhanot, O.S. *et al.* (1990) Incorporation of dA opposite N3-ethylthymidine terminates *in vitro* DNA synthesis. *Biochemistry*, **29**, 10357–10364.
120. Kang, J.O. *et al.* (1993) Methylation of RNA purine-bases by methyl radicals. *Arch. Biochem. Biophys.*, **306**, 178–182.
121. Augusto, O. *et al.* (1990) Formation of 8-methylguanine as a result of DNA alkylation by methyl radicals generated during horseradish peroxidase-catalyzed oxidation of methylhydrazine. *J. Biol. Chem.*, **265**, 22093–22096.
122. Netto, L.E. *et al.* (1992) Identification of C8-methylguanine in the hydrolysates of DNA from rats administered 1,2-dimethylhydrazine. Evidence for *in vivo* DNA alkylation by methyl radicals. *J. Biol. Chem.*, **267**, 21524–21527.
123. Gasparuto, D. *et al.* (2002) Excision of 8-methylguanine site-specifically incorporated into oligonucleotide substrates by the AlkA protein of *Escherichia coli*. *DNA Repair*, **1**, 437–447.
124. Kohda, K. *et al.* (1996) Synthesis, miscoding specificity, and thermodynamic stability of oligodeoxynucleotide containing 8-methyl-2'-deoxyguanosine. *Chem. Res. Toxicol.*, **9**, 1278–1284.
125. Shibutani, S. (2002) Quantitation of base substitutions and deletions induced by chemical mutagens during DNA synthesis *in vitro*. *Chem. Res. Toxicol.*, **6**, 625–629.
126. Sugiyama, H. *et al.* (1996) Synthesis, structure and thermodynamic properties of 8-methylguanine-containing oligonucleotides: Z-DNA under physiological salt conditions. *Nucleic Acids Res.*, **24**, 1272–1278.
127. Xu, Y. *et al.* (2006) Formation of the G-quadruplex and i-motif structures in retinoblastoma susceptibility genes (Rb). *Nucleic Acids Res.*, **34**, 949–954.
128. el Ghissassi, F. *et al.* (1995) Formation of 1,N6-ethenoadenine and 3,N4-ethenocytosine by lipid peroxidation products and nucleic acid bases. *Chem. Res. Toxicol.*, **8**, 278–283.
129. Chung, F.L. *et al.* (1996) Lipid peroxidation as a potential endogenous source for the formation of exocyclic DNA adducts. *Carcinogenesis*, **17**, 2105–2111.
130. Marnett, L.J. (2000) Oxyradicals and DNA damage. *Carcinogenesis*, **21**, 361–370.
131. Blair, I.A. (2001) Lipid hydroperoxide-mediated DNA damage. *Exp. Gerontol.*, **36**, 1473–1481.
132. Nair, J. *et al.* (1995) 1,N6-ethenodeoxyadenosine and 3,N4-ethenodeoxycytine in liver DNA from humans and untreated rodents detected by immunoaffinity/32P-postlabeling. *Carcinogenesis*, **16**, 613–617.
133. Barbin, A. *et al.* (2003) Endogenous deoxyribonucleic acid (DNA) damage in human tissues: a comparison of ethenobases with aldehydic DNA lesions. *Cancer Epidemiol. Biomarkers Prev.*, **12**, 1241–1247.
134. Barbin, A. (2000) Etheno-adduct-forming chemicals: from mutagenicity testing to tumor mutation spectra. *Mutat. Res.*, **462**, 55–69.
135. Hussain, S.P. *et al.* (2007) Inflammation and cancer: an ancient link with novel potentials. *Int. J. Cancer*, **121**, 2373–2380.
136. Saparbaev, M. *et al.* (1995) *Escherichia coli*, *Saccharomyces cerevisiae*, rat and human 3-methyladenine DNA glycosylases repair 1,N6-ethenoadenine when present in DNA. *Nucleic Acids Res.*, **23**, 3750–3755.
137. Engelward, B.P. *et al.* (1997) Base excision repair deficient mice lacking the Aag alkyladenine DNA glycosylase. *Proc. Natl Acad. Sci. USA*, **94**, 13087–13092.
138. Ham, A.J. *et al.* (2004) New immunoaffinity-LC-MS/MS methodology reveals that Aag null mice are deficient in their ability to clear 1,N6-etheno-deoxyadenosine DNA lesions from lung and liver *in vivo*. *DNA Repair (Amst.)*, **3**, 257–265.
139. Pandya, G.A. *et al.* (2000) *Escherichia coli* responses to a single DNA adduct. *J. Bacteriol.*, **182**, 6598–6604.
140. Basu, A.K. *et al.* (1993) Mutagenic and genotoxic effects of three vinyl chloride-induced DNA lesions: 1,N⁶-ethenoadenine, 3,N⁴-ethenocytosine, and 4-amino-5-(imidazol-2-yl)imidazole. *Biochemistry*, **32**, 12793–12801.
141. Delaney, J.C. *et al.* (2005) AlkB reverses etheno DNA lesions caused by lipid oxidation *in vitro* and *in vivo*. *Nat. Struct. Mol. Biol.*, **12**, 855–860.
142. Mishina, Y. *et al.* (2005) Direct repair of the exocyclic DNA adduct 1,N6-ethenoadenine by the DNA repair AlkB proteins. *J. Am. Chem. Soc.*, **127**, 14594–14595.
143. Guliaev, A.B. *et al.* (2004) Chloroethylnitrosourea-derived ethano cytosine and adenine adducts are substrates for *Escherichia coli* glycosylases excising analogous etheno adducts. *DNA Repair (Amst.)*, **3**, 1311–1321.
144. Guliaev, A.B. *et al.* (2002) Structural insights by molecular dynamics simulations into differential repair efficiency for ethano-A versus etheno-A

- adducts by the human alkylpurine-DNA N-glycosylase. *Nucleic Acids Res.*, **30**, 3778–3787.
145. Frick, L.E. *et al.* (2007) Alleviation of 1,N6-ethanoadenine genotoxicity by the *Escherichia coli* adaptive response protein AlkB. *Proc. Natl Acad. Sci. USA*, **104**, 755–760.
146. Cheng, K.C. *et al.* (1991) The vinyl chloride DNA derivative N2,3-ethenoguanine produces G → A transitions in *Escherichia coli*. *Proc. Natl Acad. Sci. USA*, **88**, 9974–9978.
147. Lee, S.H. *et al.* (2005) 4-Hydroperoxy-2-nonenal-induced formation of 1,N2-etheno-2'-deoxyguanosine adducts. *Chem. Res. Toxicol.*, **18**, 780–786.
148. Langouet, S. *et al.* (1997) Misincorporation of dNTPs opposite 1,N2-ethenoguanine and 5,6,7,9-tetrahydro-7-hydroxy-9-oxoimidazo[1,2-a]purine in oligonucleotides by *Escherichia coli* polymerases I exo- and II exo-, T7 polymerase exo-, human immunodeficiency virus-1 reverse transcriptase, and rat polymerase beta. *Biochemistry*, **36**, 6069–6079.
149. Sapparbaev, M. *et al.* (2002) 1,N(2)-ethenoguanine, a mutagenic DNA adduct, is a primary substrate of *Escherichia coli* mismatch-specific uracil-DNA glycosylase and human alkylpurine-DNA-N-glycosylase. *J. Biol. Chem.*, **277**, 26987–26993.
150. Matijasevic, Z. *et al.* (1992) Release of N2,3-ethenoguanine from chloroacetaldehyde-treated DNA by *Escherichia coli* 3-methyladenine DNA glycosylase II. *Proc. Natl Acad. Sci. USA*, **89**, 9331–9334.
151. Sapparbaev, M. *et al.* (1998) 3,N4-ethenocytosine, a highly mutagenic adduct, is a primary substrate for *Escherichia coli* double-stranded uracil-DNA glycosylase and human mismatch-specific thymine-DNA glycosylase. *Proc. Natl Acad. Sci. USA*, **95**, 8508–8513.
152. Hanahan, D. *et al.* (2000) The hallmarks of cancer. *Cell*, **100**, 57–70.
153. Zong, W.X. *et al.* (2004) Alkylating DNA damage stimulates a regulated form of necrotic cell death. *Genes Dev.*, **18**, 1272–1282.
154. DeBerardinis, R.J. *et al.* (2007) Beyond aerobic glycolysis: transformed cells can engage in glutamine metabolism that exceeds the requirement for protein and nucleotide synthesis. *Proc. Natl Acad. Sci. USA*, **104**, 19345–19350.
155. Loeb, L.A. *et al.* (2008) Cancers exhibit a mutator phenotype: clinical implications. *Cancer Res.*, **68**, 3551–3557.
156. Suspène, R. *et al.* (2005) Extensive editing of both hepatitis B virus DNA strands by APOBEC3 cytidine deaminases *in vitro* and *in vivo*. *Proc. Natl Acad. Sci. USA*, **102**, 8321–8326.
157. Goodman, M.F. *et al.* (2007) AID-initiated purposeful mutations in immunoglobulin genes. In Frederick, W.A. and Tasuku, H. (eds.) *Advances in Immunology*. Academic Press, pp. 127–155.
158. Chelico, L. *et al.* (2009) Stochastic properties of processive cytidine DNA deaminases AID and APOBEC3G. *Phil. Trans. R. Soc. B.*, **364**, 583–593.
159. Neeley, W.L. *et al.* (2007) DNA polymerase V allows bypass of toxic guanine oxidation products *in vivo*. *J. Biol. Chem.*, **282**, 12741–12748.
160. Kabnick, K.S. *et al.* (1988) Determinants that contribute to cytoplasmic stability of human *c-fos* and β -globin mRNAs are located at several sites in each mRNA. *Mol. Cell. Biol.*, **8**, 3244–3250.
161. Morceau, F. *et al.* (2000) GTP-mediated differentiation of the human K562 cell line: transient overexpression of GATA-1 and stabilization of the gamma-globin mRNA. *Leukemia*, **14**, 1589–1597.
162. Yi, X. *et al.* (1999) Both transcriptional and posttranscriptional mechanisms regulate human telomerase template RNA levels. *Mol. Cell. Biol.*, **19**, 3989–3997.
163. Kreuzer, D.A. *et al.* (1998) Oxidized, deaminated cytosines are a source of C → T transitions *in vivo*. *Proc. Natl Acad. Sci. USA*, **95**, 3578–3582.
164. Loeb, L.A. *et al.* (2000) Lethal mutagenesis of HIV by mutagenic ribonucleoside analogs. *AIDS Res. Hum. Retroviruses*, **16**, 1–3.

Received August 19, 2009; revised October 20, 2009;
accepted October 21, 2009